Woonsocket

Researchers are studying how zuranolone affects symptoms of postpartum depression (PPD) in adults who took the medication within one year after giving birth. Postpartum depression can cause tiredness, sadness, and loss of interest in daily activities. This observational study collects health information from people prescribed zuranolone through CVS Specialty Pharmacy in the United States between June 2025 and May 2026. The main goal is to see how zuranolone changes PPD symptoms by using the Edinburgh Postnatal Depression Scale (EPDS). Participants who filled their zuranolone prescription will be contacted and invited to join the study. Those who agree will complete questionnaires about their symptoms, background, environment, and general health. Participants must take their first dose of zuranolone within 7 days of joining. They will then complete the EPDS questionnaire at 15 days and again at 45 days after the first dose. The study also tracks breastfeeding status and use of other medications during the 45-day period. Throughout the study, participants will answer surveys and the EPDS tool to measure their depression symptoms. Researchers will observe changes in EPDS scores at Day 15 and Day 45, breastfeeding rates while on zuranolone, and medication use before, during, and after treatment. The study aims to understand how zuranolone helps with PPD symptoms and how participants manage their health over the study period.

Researchers are evaluating a technology-based collaborative care program called RI-SPHERES for postpartum people with hypertensive disorders of pregnancy. The trial aims to compare RI-SPHERES to a standard self-measured blood pressure program to see if it is not worse in controlling persistent high blood pressure six weeks after childbirth and improving preventive care visits within one year. The study addresses gaps in current blood pressure monitoring programs, especially for racial and ethnic minority groups who face barriers to in-person care. Participants are randomly assigned to either the RI-SPHERES group or the standard program group. The RI-SPHERES group learns to use a Bluetooth-enabled blood pressure cuff that syncs with an app providing automated reminders, educational content, and two-way communication with care managers for one year postpartum. The care manager supports participants with social needs and facilitates preventive care appointments after six weeks. The standard program involves self-measuring blood pressure and reporting it through a patient portal with reminders and recommendations for follow-up care at six weeks postpartum. During the study, participants will perform regular blood pressure measurements and communicate with care teams through the assigned program. Researchers will track persistent hypertension at six weeks postpartum and preventive care attendance within one year. The study includes assessments of equity based on race, ethnicity, language, and geography. The total participation covers one year postpartum, with ongoing support and monitoring to reduce health complications related to hypertensive disorders of pregnancy.